Follow real-time updates on Union Budget 2023Catch exclusive videos on Union Budget 2023 from CNBC-TV18
Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd, is considering a sale of Indian drugmaker Gland Pharma Ltd. after receiving interest from potential buyers. Hyderabad-based Gland specialises in injectable drugs such as antibiotics, oncology and cardiology treatments.
Billionaire Guo Guangchang’s Shanghai Fosun Pharmaceutical Group Co. is considering a sale of Indian drugmaker Gland Pharma Ltd. after receiving interest from potential buyers, people familiar with the matter said.
Recommended ArticlesView All
Budget 2023: Taking a bold step to unlock India’s potential
Feb 2, 2023 IST2 Min(s) Read
Budget 2023: Moving closer towards universal health through proper implementation is key
Feb 2, 2023 IST3 Min(s) Read
Explained: Pakistan economy on the edge of collapse — why India may be worried
Feb 2, 2023 IST10 Min(s) Read
Budget 2023: Unleashing India’s growth potential in the years to come
Feb 2, 2023 IST2 Min(s) Read
Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said. Companies in the industry and buyout firms are in the early stages of studying the business, the people said, asking not to be identified because the matter is private.
Shares of Gland jumped as much as 5.7 percent in Mumbai following the Bloomberg News report, their largest intraday increase in almost a month. They have fallen about 53 percent this year, giving the company a market value of $3.6 billion. Fosun Pharma shares in Hong Kong rose as much as 5.4 percent.
Hyderabad-based Gland specializes in injectable drugs such as antibiotics, oncology and cardiology treatments and has a presence in about 60 countries, according to its website.
A sale would help Gland’s Chinese owner raise cash as the once-acquisitive group seeks to shore up its balance sheet. Fosun International has been exploring options for a number of assets, including French resort operator Club Med and some domestic food and beverage operations, Bloomberg News has reported.
Fosun Pharma’s high valuation expectations could present a hurdle to any potential deal amid a tough financing environment, the people said. It hasn’t kicked off a formal sale process, and there’s no certainty the deliberations will lead to a transaction, the people said.
Representatives for Fosun Pharma didn’t immediately respond to requests for comment, while a spokesperson for Gland declined to comment.
Fosun Pharma acquired a 74 percent stake in Gland for about $1.1 billion in 2017 from an investor group including KKR & Co. It listed the business three years later in an $873 million initial public offering in Mumbai, according to data compiled by Bloomberg.
(Edited by : Sangam Singh)
First Published: Nov 29, 2022 2:22 PM IST